TY - GEN A1 - Braune, Steffen A1 - Krüger-Genge, Anne A1 - Kammerer, Sarah A1 - Jung, Friedrich A1 - Küpper, Jan-Heiner T1 - Phycocyanin from Arthrospira platensis as Potential Anti-Cancer Drug: Review of In Vitro and In Vivo Studies T2 - Life Y1 - 2021 UR - https://www.mdpi.com/2075-1729/11/2/91 U6 - https://doi.org/10.3390/life11020091 VL - 11 IS - 2 SP - 91 ER - TY - GEN A1 - Krüger-Genge, Anne A1 - Jung, Conrad H. G. A1 - Braune, Steffen A1 - Harb, K. A1 - Westphal, S. A1 - Klöpzig, Stefanie A1 - Küpper, Jan-Heiner A1 - Jung, Friedrich T1 - Effect of Arthrospira powders from different producers on the formation of endothelial cell monolayers T2 - Clinical Hemorheology and Microcirculation N2 - Arthrospira platensis (AP) and some of its derived products have well-established biological activities as antioxidants or as agents to reduce cardiovascular disease risk factors. Furthermore, AP products have gained increasing importance as potential anti-cancer agents. However, the ingredients of the available products vary greatly with the origin, the type of production and processing, which could have significant consequences for their biological effects. Therefore, the composition and biological influence of five distinct AP powders, which were acquired commercially or produced at a public biotechnology institute, were investigated in regard to their endothelialization capacity using a cell impedance- (CI) based measurement method. The study revealed that the AP composition and especially the influence on HUVEC proliferation differed significantly between the five AP powders up to 109%. Thus, it could be shown that the method used allows the reliable detection of quantitative differences in biological effects of different AP preparations. KW - Arthrospira platensis KW - spirulina KW - endothelial cells Y1 - 2021 UR - https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch219200 U6 - https://doi.org/10.3233/CH-219200 SN - 1875-8622 SN - 1386-0291 VL - 79 IS - 1 SP - 193 EP - 203 ER - TY - GEN A1 - Küpper, Jan-Heiner A1 - Krüger-Genge, Anne A1 - Jung, Friedrich T1 - 40th conference of the German society for clinical microcirculation and hemorheology (DGKMH) T2 - Clinical Hemorheology and Microcirculation Y1 - 2021 U6 - https://doi.org/10.3233/ch-219100 SN - 1875-8622 SN - 1386-0291 VL - 79 IS - 1 SP - 1 EP - 2 ER - TY - GEN A1 - Jung, Ernst Michael A1 - Moran, Valentina Ocañaa A1 - Engel, Martin A1 - Krüger-Genge, Anne A1 - Stroszczynski, Christian A1 - Jung, Friedrich T1 - Modified contrast-enhanced ultrasonography with the new high-resolution examination technique of high frame rate contrast-enhanced ultrasound (HiFR-CEUS) for characterization of liver lesions: First results T2 - Clinical Hemorheology and Microcirculation Y1 - 2022 U6 - https://doi.org/10.3233/CH-221449 SN - 1875-8622 SP - 1 EP - 16 ER - TY - GEN A1 - Jung, Friedrich A1 - Braune, Steffen A1 - Jung, Conrad H. G. A1 - Krüger-Genge, Anne A1 - Waldeck, Peter A1 - Petrick, Ingolf A1 - Küpper, Jan-Heiner T1 - Lipophilic and Hydrophilic Compounds from Arthrospira platensis and Its Effects on Tissue and Blood Cells—An Overview T2 - Life Y1 - 2022 U6 - https://doi.org/10.3390/life12101497 SN - 2075-1729 VL - 12 IS - 10 ER - TY - GEN A1 - Braune, Steffen A1 - Krüger-Genge, Anne A1 - Köhler, S. A1 - Küpper, Jan-Heiner A1 - Jung, Friedrich T1 - Effects of Arthrospira platensis-derived substances on blood cells T2 - Clinical Hemorheology and Microcirculation Y1 - 2022 U6 - https://doi.org/10.3233/CH-229103 SN - 1875-8622 VL - 85(2023) IS - 3 SP - 315 EP - 321 ER - TY - GEN A1 - Jung, Friedrich A1 - Lamby, Philipp A1 - Prantl, Lukas A1 - Wiggermann, P. A1 - Jung, Ernst Michael A1 - Krüger-Genge, Anne A1 - Franke, Ralf-Peter T1 - Post-mortem distribution of Iodinated Contrast Media (ICM) (iodixanol versus iopromide) in the porcine kidney after multiple bolus injections in vivo into the supra-renal aorta T2 - Clinical Hemorheology and Microcirculation Y1 - 2022 U6 - https://doi.org/10.3233/CH-229102 SN - 1875-8622 VL - 85(2023) IS - 3 SP - 289 EP - 295 ER - TY - GEN A1 - Krüger-Genge, Anne A1 - Köhler, Susanne A1 - Laube, Markus A1 - Haileka, Vanessa A1 - Lemm, Sandy A1 - Majchrzak, Karolina A1 - Kammerer, Sarah A1 - Schulz, Christian A1 - Storsberg, Joachim A1 - Pietzsch, Jens A1 - Küpper, Jan-Heiner A1 - Jung, Friedrich T1 - Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis T2 - Cells N2 - Cancer patients are at a very high risk of serious thrombotic events, often fatal. The causes discussed include the detachment of thrombogenic particles from tumor cells or the adverse effects of chemotherapeutic agents. Cytostatic agents can either act directly on their targets or, in the case of a prodrug approach, require metabolization for their action. Cyclophosphamide (CPA) is a widely used cytostatic drug that requires prodrug activation by cytochrome P450 enzymes (CYP) in the liver. We hypothesize that CPA could induce thrombosis in one of the following ways: (1) damage to endothelial cells (EC) after intra-endothelial metabolization; or (2) direct damage to EC without prior metabolization. In order to investigate this hypothesis, endothelial cells (HUVEC) were treated with CPA in clinically relevant concentrations for up to 8 days. HUVECs were chosen as a model representing the first place of action after intravenous CPA administration. No expression of CYP2B6, CYP3A4, CYP2C9 and CYP2C19 was found in HUVEC, but a weak expression of CYP2C18 was observed. CPA treatment of HUVEC induced DNA damage and a reduced formation of an EC monolayer and caused an increased release of prostacyclin (PGI2) and thromboxane (TXA) associated with a shift of the PGI2/TXA balance to a prothrombotic state. In an in vivo scenario, such processes would promote the risk of thrombus formation. KW - cancer KW - cyclophosphamide KW - human umbilical vein endothelial cells KW - HUVEC KW - liver KW - cytochrome P450 enzymes (CYP) KW - thrombosis Y1 - 2023 UR - https://www.mdpi.com/2073-4409/12/15/1965 U6 - https://doi.org/10.3390/cells12151965 SN - 2073-4409 VL - 12 IS - 15 ER - TY - GEN A1 - Krüger-Genge, Anne A1 - Harb, Kudor A1 - Braune, Steffen A1 - Jung, Conrad H. G. A1 - Westphal, Sophia A1 - Bär, Stefanie A1 - Mauger, Olivia A1 - Küpper, Jan-Heiner A1 - Jung, Friedrich ED - Georgianos, Panagiotis T1 - Effects of arthrospira platensis on human Uumbilical vein endothelial cells T2 - Life N2 - Atherosclerosis is initiated by injury or damage to the vascular endothelial cell monolayer. Therefore, the early repair of the damaged vascular endothelium by a proliferation of neighbouring endothelial cells is important to prevent atherosclerosis and thrombotic events. Arthrospira platensis (AP) has been used as a dietary supplement, mainly due to its high content of vitamins, minerals, amino acids, and pigments such as chlorophylls, carotenoids, and phycocyanin, ingredients with antioxidant, anti-inflammatory, and anti-thrombotic properties. Therefore, in this prospective, placebo-controlled, data-driven, sample-size-estimated in vitro study, we tested whether an aqueous extract of AP at different concentrations (50, 100, and 200 µg/mL) had an effect on the different cellular parameters of human umbilical vein endothelial cells. Therefore, cell impedance measurement and cell proliferation were measured to investigate the monolayer formation. In addition, cell viability, integrity, and metabolism were analysed to evaluate singular cellular functions, especially the antithrombotic state. Furthermore, cell–cell and cell–substrate interactions were observed. The highest proliferation was achieved after the addition of 100 µg/mL. This was consistently confirmed by two independent optical experiments in cell cultures 48 h and 85 h after seeding and additionally by an indirect test. At this concentration, the activation or dysfunction of HUVECs was completely prevented, as confirmed by prostacyclin and interleukin-6 levels. In conclusion, in this study, AP induced a significant increase in HUVEC proliferation without inducing an inflammatory response but altered the hemostasiological balance in favour of prostacyclin over thromboxane, thereby creating an antithrombotic state. Thus, APE could be applied in the future as an accelerator of endothelial cell proliferation after, e.g., stent placement or atherosclerosis. KW - human umbilical vein endothelial cells KW - HUVEC Y1 - 2024 U6 - https://doi.org/10.3390/life14101253 SN - 2075-1729 VL - 14 IS - 10 PB - MDPI ER -